Oxybutynin-Associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment
Anticholinergic medications have long been mainstays of overactive bladder (OAB) treatment. Oxybutynin, a first-generation anticholinergic, still accounts for more than half of all OAB medication prescriptions, despite associations with impaired memory and cognition, as well as mounting evidence that it may increase the risk of incident dementia. This review details the current literature regarding oxybutynin and cognition, including evidence from preclinical, clinical, and real-world studies that show that oxybutynin binds nonspecifically to muscarinic receptors in the brain and is associated with adverse cognitive outcomes.
Source: Urology - Category: Urology & Nephrology Authors: Michael B. Chancellor, Alvaro Lucioni, David Staskin Source Type: research
More News: Brain | Dementia | Neurology | Overactive Bladder | Overactive Bladder Syndrome | Oxybutynin | Study | Urology & Nephrology